glp 1 ra ozempic Ozempic® (semaglutide) GLP-1 for Type 2 Diabetes How GLP-1 medications are transforming
Description
New dual agonists (GIP/GLP-1) are showing profound impact not only on weight loss and glycemic control but also on cardiovascular outcomes
There is a temptation, when facing the kind of demand disruption that GLP-1 represents, to treat it as existential and respond with wholesale portfolio transformation, but that response carries its own risks
The highest risk was in semaglutide (HR=1.39), then liraglutide (HR=1.25)
Approximately 60% of insurance plans include medications for obesity-related conditions, although they often have stringent criteria for coverage
